Study of the Verve RPD™ Renal Pelvic Denervation System Shows 20.3 mm Hg Reduction in Blood Pressure in Patients with Uncontrolled Hypertension PHOENIX–(BUSINESS WIRE)–Verve Medical, Inc. (“Verve”) today announced the detailed results from a feasibility trial evaluating a novel ablation therapy that achieved therapeutically significant blood pressure (“BP”) reduction for […]
Author: Ken Dropiewski
Investor Insights: Rob Barmann – Transitioning from Corporate Development to Venture Capital (Part 1)
McDermott + Bull Partner Ken Dropiewski talks with Endeavour Vision Partner Rob Barmann about his journey from corporate development to venture capital.
New HeartBeam Patent for 12-Lead Electrocardiogram (ECG) Smartwatch-based Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias
Patent Opens Pathway to Disruptive Ischemia and Arrhythmia Detection Product in Multi-billion Dollar Wearables Device Market SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced today that its patent for a […]
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension
Successfully Met Primary and Secondary Endpoints, with Mean Placebo-Adjusted Reduction in Systolic Blood Pressure of 9.7 mmHg in Uncontrolled and Resistant Hypertensive Subjects at 50 mg Once Daily (p=0.01 vs. placebo) Subjects Using a Thiazide Diuretic (Approximately Half of the Study Population) Showed a Mean Placebo-Adjusted Reduction in Systolic Blood […]
Vivalink Expands Biometrics Data Platform with a Portfolio of Remote Data Capture Devices and Wearable Technology
The first real-world biometrics data platform for continuous and episodic remote patient monitoring now supports Roche, OMRON, Garmin, and other wearable medical devices to power virtual healthcare applications. CAMPBELL, Calif., Nov. 16, 2022 /PRNewswire/ — Vivalink, a leading provider of digital healthcare solutions, announces physiological data from a wide range of the world’s leading […]
Route 92 Medical Announces Expansion to New Manufacturing Site in Salt Lake City, Utah
SAN MATEO, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced expansion to a new high-volume manufacturing site in Salt Lake City, Utah. This 40,000 square foot site allows Route 92 […]
Shockwave Medical Publishes Inaugural ESG Report
SANTA CLARA, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the publication of its inaugural Environmental, Social and Governance (ESG) report highlighting the company’s corporate responsibility and sustainability initiatives. […]
Viz.ai partners with Illuminate to improve quality of care for aortic aneurysm patients
Adds natural language processing to Viz.ai’s AI-powered platform to detect suspected disease earlier and monitor patients SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a partnership with Illuminate, Inc., an industry leader in the development of proprietary natural language processing (NLP) and AI software […]
Viz.ai and Vastrax Join Forces to Accelerate Clinical Trial Enrollment
Partnership to accelerate enrollment and diversity in neurovascular clinical research SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic partnership with Vastrax, the leading full-service, vascular clinical research organization (CRO). Together, Viz.ai and Vastrax will accelerate clinical trial enrollment for research on novel […]
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
EsoGuard test volume shows steady sequential growth Veris Cancer Care Platform poised for commercial launch Conference call and webcast to be held today at 4:30 PM EDT NEW YORK–(BUSINESS WIRE)–PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and […]



